Pekka V Rauhala
Overview
Explore the profile of Pekka V Rauhala including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
140
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Copie R, Blomqvist K, Farzaneh Kari M, Kurkela M, Niemi M, Rauhala P, et al.
Neuropharmacology
. 2025 Feb;
270:110369.
PMID: 39956316
The synergistic antinociceptive effects of α-adrenergic agonists and intrathecal (i.t.) opioids were initially linked to pharmacodynamics. However, the α-agonist dexmedetomidine also enhances brain delivery of CSF-administered drugs by increasing glymphatic...
2.
Ahlstrom F, Viisanen H, Karhinen L, Velagapudi V, Blomqvist K, Lilius T, et al.
IBRO Neurosci Rep
. 2024 Jun;
17:38-51.
PMID: 38933596
First-line pharmacotherapy for peripheral neuropathic pain (NP) of diverse pathophysiology consists of antidepressants and gabapentinoids, but only a minority achieve sufficient analgesia with these drugs. Opioids are considered third-line analgesics...
3.
Ahlstrom F, Viisanen H, Karhinen L, Matlik K, Blomqvist K, Lilius T, et al.
Mol Pain
. 2023 Jun;
19:17448069231183902.
PMID: 37285551
Opioids are efficacious and safe analgesic drugs in short-term use for acute pain but chronic use can lead to tolerance and dependence. Opioid-induced microglial activation may contribute to the development...
4.
Blomqvist K, Skogster M, Kurkela M, Rosenholm M, Ahlstrom F, Airavaara M, et al.
J Control Release
. 2022 Mar;
344:214-224.
PMID: 35301056
The blood-brain barrier significantly limits effective drug delivery to central nervous system (CNS) targets. The recently characterized glymphatic system offers a perivascular highway for intrathecally (i.t.) administered drugs to reach...
5.
Blomqvist K, Viisanen H, Ahlstrom F, Jokinen V, Sidorova Y, Suleymanova I, et al.
Eur J Pharmacol
. 2020 Mar;
875:173021.
PMID: 32112778
Morphine-3-glucuronide (M3G), the main metabolite of morphine, has been implicated in the development of tolerance and of opioid-induced hyperalgesia, both limiting the analgesic use of morphine. We evaluated the acute...
6.
Lilius T, Blomqvist K, Hauglund N, Liu G, Staeger F, Baerentzen S, et al.
J Control Release
. 2019 May;
304:29-38.
PMID: 31067483
Drug delivery to the central nervous system remains a major problem due to biological barriers. The blood-brain-barrier can be bypassed by administering drugs intrathecally directly to the cerebrospinal fluid (CSF)....
7.
Jokinen V, Sidorova Y, Viisanen H, Suleymanova I, Tiilikainen H, Li Z, et al.
Neuroscience
. 2018 Feb;
375:10-24.
PMID: 29421434
Development of tolerance is a well known pharmacological characteristic of opioids and a major clinical problem. In addition to the known neuronal mechanisms of opioid tolerance, activation of glia has...
8.
Lilius T, Viisanen H, Jokinen V, Niemi M, Kalso E, Rauhala P
Basic Clin Pharmacol Toxicol
. 2017 Nov;
122(5):481-488.
PMID: 29171155
Ketamine and its primary metabolite norketamine attenuate morphine tolerance by antagonising N-methyl-d-aspartate (NMDA) receptors. Ketamine is extensively metabolized to several other metabolites. The major secondary metabolite (2S,6S;2R,6R)-hydroxynorketamine (6-hydroxynorketamine) is not...
9.
Sidorova Y, Bespalov M, Wong A, Kambur O, Jokinen V, Lilius T, et al.
Front Pharmacol
. 2017 Jul;
8:365.
PMID: 28680400
Neuropathic pain caused by nerve damage is a common and severe class of chronic pain. Disease-modifying clinical therapies are needed as current treatments typically provide only symptomatic relief; show varying...
10.
Lilius T, Rauhala P, Kambur O, Rossi S, Vaananen A, Kalso E
Anesth Analg
. 2012 May;
114(6):1353-8.
PMID: 22556211
Background: Opioid analgesics are effective in the treatment of chronic pain, but they have serious adverse effects such as development of tolerance and dependence. Adrenergic α(2) agonists and μ-opioid receptor...